Business · 08/07/2019

FDA Issues Immediate Guidance on Compounding Oxitriptan for Tetrahydrobiopterin Deficiency

The FDA has released an immediately effective guidance allowing licensed pharmacists and physicians to compound oral oxitriptan (5-HTP) drug products for patients with tetrahydrobiopterin (BH4) deficiency, following a final rule that previously restricted its use.